Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIND: N-Acetylcysteine for Emotional Dysregulation in Children
NCT07323446Phase 1Not yet recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2027
- Primary completion
- Jan 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of acetylcysteine in emotional dysregulation (3 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Clinician-Young Mania Rating Scale at 8 weeks, Clinical Global Impression at 8 weeks and 1 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
acetylcysteine
03
Conditions
emotional dysregulation
Beyond the preview
Go deeper on NCT07323446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07323446.